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ABSTRACT 
The truncated non-signaling ghrelin 
receptor GHS-R1b has been suggested to simply 
exert a dominant negative role in the trafficking 
and signaling of the full and functional ghrelin 
receptor GHS-R1a. Here we reveal a more 
complex modulatory role of GHS-R1b. 
Differential co-expression of GHS-R1a and 
GHS-R1b, both in HEK-293T cells and in 
striatal and hippocampal neurons in culture, 
demonstrates that GHS-R1b acts as a dual 
modulator of GHS-R1a function: low relative 
GHS-R1b expression potentiates and high 
relative GHS-R1b expression inhibits GHS-R1a 
function by facilitating GHS-R1a trafficking to 
the plasma membrane and by exerting a negative 
allosteric effect on GHS-R1a signaling, 
respectively. We found a preferential Gi/o-
coupling of the GHS-R1a-GHS-R1b complex in 
HEK-293T cells and, unexpectedly, a 
preferential Gs/olf coupling in both striatal and 
hippocampal neurons in culture. A dopamine D1 
receptor (D1R) antagonist blocked ghrelin-
induced cAMP accumulation in striatal but not 
hippocampal neurons, indicating the 
involvement of D1R in the striatal GHS-R1a-
Gs/olf coupling. Experiments in HEK-293T 
demonstrated that D1R co-expression promotes 
a switch in GHS-R1a-G protein coupling, from 
Gi/o to Gs/olf, but only upon co-expression of 
GHS-R1b. Furthermore, resonance energy 
transfer experiments showed that D1R interacts 
with GHS-R1a, but only in the presence of 
GHS-R1b. Therefore, GHS-R1b not only 
determines the efficacy of ghrelin-induced GHS-
R1a-mediated signaling, but also determines the 
ability of GHS-R1a to form oligomeric 
complexes with other receptors promoting 
profound qualitative changes in ghrelin-induced 
signaling.  
_______________________________________ 
Ghrelin is an orexigenic hormone, an 
internal signal for the animal to engage in food-
directed behavior (1,2). It is produced by the 
stomach oxyntic cells, which provide plasma 
levels that fluctuate diurnally with a peak in the 
day and trough at night. Notably, oxyntic cells 
qualify as food-entrained oscillators and ghrelin 
plasma levels increase during anticipated 
mealtimes and decrease after meals (1). These 
and other less well-characterized central 
neuronal functions of ghrelin depend on its 
ability to cross the blood-brain barrier by still 
unclear mechanisms and reaching ghrelin 
receptors localized in specific brain areas, such 
as hypothalamus, hippocampus, amygdala, 
mesencephalic dopaminergic regions and 
striatum (2-4) 
Ghrelin acts on the class A G protein-
coupled receptor known as growth hormone 
secretagogue (GHS) receptor or GHS-R1a. Cells 
expressing GHS-R1a also express GHS-R1b, a 
truncated variant of GHS-R1a lacking the 
transmembrane domains 6 and 7. Ghrelin does 
not bind and therefore does not signal through 
GHS-R1b (5) and the role of this truncated 
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“receptor” on ghrelin-mediated signaling is just 
beginning to be understood. Evidence has been 
provided for the ability of GHS-R1a to 
homodimerize and to heterodimerize with GHS-
R1b, which might allow GHS-R1b to produce a 
dominant negative effect on GHS-R1a signaling. 
Two different mechanisms have been invoked 
for the dominant negative function of GHS-R1b: 
Intracellular retention by an inability of GHS-
R1b to traffic to the plasma membrane (6,7) and 
an allosteric mechanism that produces a 
conformational block of GHS-R1a in a non-
signaling conformation (5). Those results were 
obtained from in vitro experiments in transfected 
cells and in reconstituted lipid vesicles and, 
therefore, either mechanism could be involved in 
a physiological cellular environment. However, 
although both mechanisms do not seem 
exclusive, the intracellular retention of GHS-
R1a-GHS-R1b heteromer would render the 
reported complete blockade of G-protein 
activation and beta-arrestin recruitment (5) a 
fortuitous useless mechanism, since both 
signaling pathways originate in the plasma 
membrane. The initial aim of the present study 
was elucidating the mechanisms of GHS-R1b-
mediated modulation of GHS-R1a in a neuronal 
environment and includes signaling experiments 
performed in a mammalian cell line and primary 
neurons in culture with particular emphasis in 
the changes produced by manipulation of the 
relative expression of GHS-R1a and GHS-R1b 
in the plasma membrane. The study reveals a 
significant and complex modulatory role of 
GHS-R1b in the trafficking and signaling of 
GHS-R1a that depends on the relative 
expression of both proteins.  An unexpected 
additional finding in striatal and hippocampal 
neurons in culture was a predominant Gs/olf 
protein-dependent signaling of ghrelin, which in 
striatal neurons depended on dopamine D1 
receptor (D1R)-GHS-R1a-GHS-R1b 
heteromerization.   
 
EXPERIMENTAL PROCEDURES 
 Cell lines and neuronal primary 
cultures- Human embryonic kidney (HEK-293T) 
cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco) 
supplemented with 2 mM L-glutamine, 100 
µg/ml sodium pyruvate, 100 U/ml 
penicillin/streptomycin, MEM Non-Essential 
Amino Acids Solution (1/100) and 5% (v/v) heat 
inactivated Fetal Bovine Serum (FBS) (all 
supplements were from Invitrogen, Paisley, 
Scotland, UK). Primary cultures of striatal, 
hippocampal and cortical neurons were obtained 
from fetal Sprague Dawley rats (embryonic day 
19). Cells were isolated as described in (8) and 
plated at a confluence of 40,000 cells/0.32 cm2 
in 96 well plates for MAPK experiments and in 
6 well plates for the other assays. Cells were 
maintained in Neurobasal medium supplemented 
with 2 mM L-glutamine, 100 U/ml penicillin/ 
streptomycin, and 2% (v/v) B27 supplement 
(GIBCO) in a 96-well plate for 12 days. 
Vectors and fusion proteins- Sequences 
encoding amino acid residues 1–155 and 155–
238 of the Venus variant of Yellow 
Fluorescence Protein (YFP) and amino acids 
residues 1–229 and 230–311 of Rluc8 protein 
were subcloned in the pcDNA3.1 vector to 
obtain YFP and Rluc hemitruncated proteins. 
Human cDNAs for GHS-R1a, GHS-R1b, CB1R, 
CRF1R, or A1R, cloned into pcDNA3.1, were 
amplified without their stop codons using sense 
and antisense primers harboring: EcoRI and 
KpnI sites to clone GHS-R1a, GHS-R1b and 
CRF1R in pRLuc-N1 vector (pRLuc-N1 
PerkinElmer, Wellesley, MA) or in pEYFP-N1 
vector (enhanced yellow variant of GFP; 
Clontech, Heidelberg, Germany), HindIII and 
BamHI sites to clone A1R in pcDNA3.1cRluc8- 
vector, BamHI and EcoRI sites to clone CB1R 
in pcDNA3.1RLuc vector or EcoRI and KpnI 
sites to clone GHS-R1a receptors in a GFP2 
containing vector (p-GFP2 , Packard BioScience, 
Meridien, CT). Amplified fragments were 
subcloned to be in-frame with restriction sites of 
pRLuc-N1, pEYFP-N1 or p-GFP2 vectors to 
provide plasmids that express proteins fused to 
RLuc, YFP or GFP2 on the C-terminal end 
(GHS-R1a-Rluc, GHS-R1b-Rluc, CB1R-Rluc, 
CRF1R-Rluc, GHS-R1a-YFP, GHS-R1b-YFP or 
GHS-R1a-GFP2). For Bioluminescence 
Resonance Energy Transfer (BRET) with 
Bimolecular Fluorescence and Luminescence 
Complementation (BiFLC) experiments, cDNA 
for GHS-R1b was subcloned into pcDNA3.1-
nVenus and cDNA for GHS-R1a was subcloned 
into pcDNA3.1-cVenus to provide plasmids that 
expresses the receptor fused to the 
hemitruncated nYFP Venus or cYFP Venus on 
the C-terminal end of the receptor (GHS-R1b-
nYFP and GHS-R1a-cYFP). Also, the cDNA for 
GHS-R1b was subcloned into pcDNA3.1-
nRluc8 and the cDNA for GHS-R1a and A1R 
were subcloned into pcDNA3.1-cRluc8 to 
provide plasmids that expresses the receptor 
fused to the hemitruncated nRluc8 or cRluc8 on 
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the C-terminal end of the receptor (GHS-R1b-
nRluc, GHS-R1a-cRluc and A1R-cRluc). 
Cell transfection- HEK-293T cells and 
neuronal primary cultures growing in 6-well 
dishes were transiently transfected with the 
corresponding protein cDNA by the PEI 
(PolyEthylenImine, Sigma-Aldrich, St. Louis, 
MO) method. Cells were incubated (4 h for 
HEK-293T cells and 6 h for neurons) with the 
corresponding cDNA together with PEI (5.47 
mM in nitrogen residues) and 150 mM NaCl in a 
serum-starved medium. After 4 hours, the 
medium was changed to a fresh complete culture 
medium. Forty-eight hours after transfection, 
cells were washed twice in quick succession in 
HBSS with 10 mM glucose, detached, and 
resuspended in the same buffer. Cells were 
maintained at 37oC in an atmosphere of 5% CO2.  
Resonance energy transfer-based 
assays- For BRET assays, HEK-293T cells were 
transiently co-transfected with a constant cDNA 
encoding for receptor-Rluc and with increasing 
amounts of cDNA corresponding to receptor-
YFP or receptor-GFP2. To control the cell 
number, sample protein concentration was 
determined using a Bradford assay kit (Bio-Rad, 
Munich, Germany) using bovine serum albumin 
dilutions as standards. To quantify fluorescence 
proteins, cells (20 µg protein) were distributed in 
96-well microplates (black plates with a 
transparent bottom) and fluorescence was read in 
a Fluostar Optima Fluorimeter (BMG Labtech, 
Offenburg, Germany) equipped with a high-
energy xenon flash lamp, using a 10 nm 
bandwidth excitation filter at 410 nm for 
receptor-GFP2 reading or 485 nm for receptor-
YFP reading. Receptor-fluorescence expression 
was determined as fluorescence of the sample 
minus the fluorescence of cells expressing 
receptor-Rluc alone. For BRET measurements, 
the equivalent of 20 µg of cell suspension were 
distributed in 96 well white microplates with 
white bottom (Corning 3600, Corning, NY) and 
5 µM of coelenterazine H (for YFP acceptor) or 
DeepBlueC (for GFP2 acceptor) (Molecular 
Probes, Eugene, OR) were added. Using 
DeepBlueC or coelenterazine H as substrates 
results in respective 410 nm and 485 nm 
emissions from Rluc, which allow the respective 
selective energy transfer to GFP2 and YFP (14). 
One minute after adding coelenterazine H or 
immediately after addition of DeepBlueC BRET 
was determined using a Mithras LB 940 reader 
(Berthold Technologies, DLReady, Germany), 
which allows the integration of the signals 
detected in the short-wavelength filter at 485 nm 
and the long-wavelength filter at 530 nm when 
YFP is the acceptor, or short-wavelength filter at 
400 nm and the long-wavelength filter at 510 nm 
when GFP2 is the acceptor. To quantify receptor-
Rluc expression luminescence readings were 
performed after 10 minutes of adding 5 µM of 
coelenterazine H irrespective of the acceptor 
used. Net BRET is defined as [(long-wavelength 
emission)/(short-wavelength emission)]-Cf 
where Cf corresponds to [(long-wavelength 
emission)/(short-wavelength emission)] for the 
Rluc construct expressed alone in the same 
experiment. For BiFC and BiLC assays, HEK-
293T cells were transiently co-transfected with a 
constant amount of cDNA encoding for proteins 
fused to nRLuc8 or cRLuc8, and with increasing 
amounts of the cDNA corresponding to proteins 
fused to nYFP Venus or cYFP Venus. The 
complemented YFP Venus or Rluc8 expression 
and BRET were quantified as above described. 
For Sequence Resonance Energy Transfer 
(SRET) assays (14), HEK-293T cells were 
transiently co-transfected with constant amounts 
of cDNAs encoding for both receptor fused to 
RLuc or GFP2 and with increasingly amounts of 
cDNA corresponding to the receptor fused to 
YFP. Using aliquots of transfected cells (20 µg 
of protein), different determinations were 
performed in parallel: (i) Quantification of 
protein-YFP expression and (ii) quantification of 
protein-Rluc expression as above described. (iii) 
For SRET, cells were distributed in 96-well 
microplates and 5 µM DeepBlueC was added. 
SRET signal was collected using the Mithras LB 
940 reader with detection filters for short 
wavelength (410 nm) and long wavelength (530 
nm). By analogy with BRET, net SRET is 
defined as ((long wavelength emission)/(short 
wavelength emission)) - Cf, where Cf 
corresponds to long wavelength emission/short 
wavelength emission for cells expressing 
protein-Rluc and protein-GFP2. Linear unmixing 
was done for SRET quantification, taking into 
account the spectral signature to separate the two 
fluorescence emission spectra (9). SRET is 
expressed as mili SRET units, mSU (net SRET x 
1000).  
Immunocytochemistry- Transiently 
transfected HEK-293T cells were fixed in 4% 
paraformaldehyde for 15 min and washed with 
PBS containing 20 mM glycine (buffer A) to 
quench the aldehyde groups. After 
permeabilization with buffer A containing 0.2% 
Triton X-100 for 5 min, cells were treated with 
 at U
N
IV
 O
F EA
ST A
N
G
LIA
 on A
pril 27, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Functional role of the truncated ghrelin receptor 	
	 4	
PBS containing 1% bovine serum albumin. After 
1 h at room temperature, cells expressing 
receptor-Rluc were labelled with a primary 
mouse monoclonal anti-Rluc antibody (1/100, 
EMD Millipore, Darmstadt, Germany) for 1 h, 
washed, and stained with a secondary antibody 
for Cy3 Donkey anti-mouse (1/100, Jackson 
Immunoresearch Laboratories, Baltimore, PA, 
USA). Receptors fused to YFP were detected by 
their fluorescence properties. Samples were 
rinsed and observed in a Leica SP2 confocal 
microscope or a SP5 confocal microscopy for 
DsRed (Leica Microsystems, Mannheim, 
Germany). 
Western blotting- To determine the 
GHS-R1a-YFP, GHS-R1b-YFP or the CB1R-
YFP expression levels in transfected HEK-293T 
cells, equivalent amounts of cell protein (10 µg) 
were separated by electrophoresis on a 
denaturing 10% SDS-polyacrylamide gel and 
transferred onto PVDF-fluorescence membranes. 
Membranes were probed with a mixture of a 
mouse anti-β-tubulin antibody (1:2000; Sigma-
Aldrich) and a rabbit anti-YFP antibody 
(1:1,000; Santa Cruz, Dallas, TX) and a mixture 
of IRDye 800 (anti-mouse) antibody (1:10,000; 
Sigma-Aldrich) and IRDye 680 (anti-rabbit) 
antibody (1:10,000; Sigma). Bands were 
scanned using the Odyssey infrared scanner (LI-
COR Biotechnology, Lincoln, NE). Band 
densities were quantified using the scanner 
software and receptor level was normalized for 
differences in loading using tubulin protein band 
intensities. 
Biotinylation experiments- Cell surface 
proteins were biotinylated as described 
previously (9) using HEK-293T cells transiently 
expressing GHS-R1a-YFP and increasing 
amounts of GHS-R1b-Rluc or CB1R-Rluc or 
expressing increasing amounts of GHS-R1b-
Rluc. Cells were washed three times with borate 
buffer (10 mM H3BO3, pH 8.8; 150 mM NaCl) 
and incubated with 50 µg/mL sulfo-NHS-LC-
biotin (Thermo Fisher Scientific, Halethorpe, 
MD) in borate buffer for 5 min at room 
temperature. Cells were then washed three times 
in borate buffer and again incubated with 50 
µg/mL sulfo-NHS-LC-biotin in borate buffer for 
10 min at room temperature, followed by 
addition of 13 mM NH4Cl for 5 min to quench 
the remaining biotin. Cells were washed in PBS, 
disrupted with three 10 s strokes in a polytron 
and centrifuged at 16 000 g for 30 min. The 
pellet was solubilized in an ice-cold RIPA buffer 
(50 mM Tris–HCl, 1% Triton X-100, 0.2% SDS, 
100 mM NaCl, 1 mM EDTA, 0.5% sodium 
deoxycholate) for 30 min and centrifuged at 16 
000 g for 20 min. The supernatant was incubated 
with 80 µL streptavidin-agarose beads (Sigma-
Aldrich) for 1 h with constant rotation at 4°C. 
Beads were washed three times with ice-cold 
lysis buffer and aspirated to dryness with a 28-
gauge needle. Subsequently, 50 µl of SDS–
PAGE sample buffer (8 M Urea, 2% SDS, 100 
mM dithiothreitol, 375 mM Tris, pH 6.8) were 
added to each sample. Proteins were dissociated 
by heating to 37°C for 2 h and resolved by SDS-
polyacrylamide gel electrophoresis in 10% gels 
and immunoblotted as described above. 
RT-PCR assay- Total cellular RNA was 
isolated from neuronal cultures using QuickPrep 
Total RNA Extraction Kit (Amersham 
Biosciences, Piscataway, NJ). Total RNA (1 µg) 
was reverse-transcribed by random priming 
using M-MLV reverse transcriptase, RNase H 
minus, point mutant, following the protocol of 
“Two-Step RT-PCR” provided by Promega 
(Promega, Madison, WI, USA). The resulting 
single-stranded cDNA was used to perform PCR 
amplification for GHS-R1a and GHS-R1b and 
GAPDH as an internal control of PCR technique 
using Taq DNA Polymerase (Promega). A rat 
GHS-R1a and GHS-R1b common forward 
primer 5’-GCTCTTCGTGGTGGGCATCT-3’ 
was used. To amplify GHS-R1a the 5’-
GAGAAGGATTCAAATCCTAGCA-3’ reverse 
primer was used corresponding to a nucleotide 
sequence coding for the 7 TM domain, not 
present in GHS-R1b. To amplify GHS-R1b the 
5’-TCAGCGGGTGCCAGGACTC-3’ reverse 
primer was used corresponding to a nucleotide 
sequence coding for the 5 TM domain not 
present in GHS-R1a. To amplify GAPDH the 
primers used were 5’-
CATCCTGCACCACCAACTGCTTAG-3’ 
(forward) and 5’-
GCCTGCTTCACCACCTTCTTGATG -3’ 
(reverse). RNA without reverse transcriptions 
did not yield any amplicons, indicating that there 
was no genomic DNA contamination.  
Dynamic mass redistribution (DMR) 
label free assays- Cell signaling was explored 
using an EnSpire® Multimode Plate Reader 
(PerkinElmer, Waltham, MA, USA) by a label-
free technology. Refractive waveguide grating 
optical biosensors, integrated in 384-well 
microplates, allow extremely sensitive 
measurements of changes in local optical density 
in a detecting zone up to 150 nm above the 
surface of the sensor. Cellular mass movements 
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induced upon receptor activation were detected 
by illuminating the underside of the biosensor 
with polychromatic light and measured as 
changes in wavelength of the reflected 
monochromatic light that is a sensitive function 
of the index of refraction. The magnitude of this 
wavelength shift (in picometers) is directly 
proportional to the amount of DMR. Briefly, 
HEK-293T cells or neurons were seeded in 384-
well sensor microplates to obtain 70-80% 
confluent monolayers. Prior to the assay, cells 
were washed twice with assay buffer (HBSS 
with 20 mM HEPES, pH 7.15) and incubated for 
2 h in the reader at 24°C in 30 µl/well of vehicle 
(assay-buffer with 0.1% DMSO). Hereafter, the 
sensor plate was scanned and a baseline optical 
signature was recorded before adding 10 µl of 
test compound dissolved in vehicle. Then, DMR 
responses were monitored for at least 5000 s. 
Kinetic results were analyzed using EnSpire 
Workstation Software v 4.10. 
cAMP accumulation- Homogeneous 
time-resolved fluorescence energy transfer 
(HTRF) assays were performed using the Lance 
Ultra cAMP kit (PerkinElmer). The optimal cell 
density was first established for an appropriate 
fluorescent signal by measuring the TR-FRET 
signal as a function of forskolin concentration 
using different cell densities. Forskolin dose-
response curves were related to the cAMP 
standard curve in order to establish which cell 
density provides a response that covers most of 
the dynamic range of cAMP standard curve. 
Cells (5,000 HEK-293T cells or neurons/well in 
384-well microplates) growing in medium 
containing 50 µM zardeverine were pre-treated 
with the antagonists or the corresponding vehicle 
at 25°C for 20 min, and stimulated with agonists 
for 15 min before adding 0.5 µM forskolin or 
vehicle, and incubating for an additional 15 min 
period. Fluorescence at 665 nm was analyzed on 
a PHERAstar Flagship microplate reader 
equipped with an HTRF optical module (BMG 
Labtech).  
Intracellular calcium release- Cells 
were co-transfected with the cDNA for the 
indicated receptors and 3 µg of GCaMP6 
calcium sensor (10) using lipofectamine 2000 
(Thermo Fisher Scientific) method. 48 h after 
transfection, cells (150.000 HEK-293T 
cells/well in 96-well black, clear bottom 
microtiter plates) were incubated with Mg+2-free 
Locke’s buffer pH 7.4 (154 mM NaCl, 5.6 mM 
KCl, 3.6 mM NaHCO3, 2.3 mM CaCl2, 5.6 mM 
glucose and 5 mM HEPES) supplemented with 
10 µM glycine and receptor ligands were added 
as indicated. Fluorescence emission intensity of 
GCaMP6 was recorded at 515 nm upon 
excitation at 488 nm on the EnSpire® 
Multimode Plate Reader for 335 s every 15 s and 
100 flashes per well.  
Arrestin recruitment assays- Arrestin 
recruitment was determined using BRET 
experiments as described above in HEK-293T 
cells expressing the cDNA corresponding to β-
arrestin-2-Rluc (1 µg transfected), GHS-R1a-
YFP (1,5 µg transfected) alone or with GHS-
R1b (0.05 to 0,5 µg transfected) after the 
indicated treatment with ligands. 
ERK1/2 phosphorylation- HEK-293T 
cells (30,000 cells/well in 96-well plates) were 
treated with vehicle or the indicated ligand for 
the indicated time and were lysed by the addition 
of ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 
50 mM NaF, 150 mM NaCl, 45 mM β-
glycerophosphate, 1% Triton X-100, 20 µM 
phenyl-arsine oxide, 0.4 mM NaVO4 and 
protease inhibitor cocktail). Cellular debris was 
removed by centrifugation at 13,000 x g for 5 
min at 4oC and the protein was quantified by the 
bicinchoninic acid method using bovine serum 
albumin dilutions as standard. Equivalent 
amounts of protein (10 µg) were separated by 
electrophoresis (10% SDS-polyacrylamide gel) 
and transferred onto PVDF-fluorescence 
membranes. Membranes were probed with a 
mixture of a mouse anti-phospho-ERK1/2 
antibody (1:2500; Sigma-Aldrich) and a rabbit 
anti-ERK1/2 antibody that recognizes both 
phosphorylated and non-phosphorylated ERK1/2 
(1:40,000; Sigma-Aldrich) and bands were 
visualized by the addition of a mixture of IRDye 
800 (anti-mouse) antibody (1:10,000; Sigma-
Aldrich) and IRDye 680 anti-rabbit antibody 
(1:10,000; Sigma-Aldrich) and scanned by the 
Odyssey infrared scanner. Bands densities were 
quantified using the scanner software and the 
level of phosphorylated ERK1/2 isoforms was 
normalized for differences in loading using the 
total ERK1/2 protein band intensities. 
 
RESULTS 
GHS-R1b-mediated modulation GHS-
R1a expression at the plasma membrane in 
transfected HEX-293T cells- The role of GHS-
R1b on GHS-R1a expression in the plasma 
membrane was evaluated first by analyzing 
GHS-R1a expression by immunocytochemistry 
and confocal microscopy in HEK-293T cells 
transfected with cDNA of GHS-R1a fused to 
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YFP (GHS-R1a-YFP; 1 µg), GHS-R1b fused to 
Rluc (GHS-R1b-Rluc; 0.5 µg) or both. Both 
GHS-R1a-YFP (Fig. 1A, identified by its own 
fluorescence) and GHS-R1b-Rluc (Fig. 1B, 
identified by anti-Rluc and secondary Cy3 
antibodies; see methods), when expressed alone, 
could be detected in intracellular structures and 
at the plasma membrane level. Some degree of 
co-localization could be observed upon of GHS-
R1a-YFP and GHS-R1b-Rluc co-transfection 
(Figure 1C). Fused receptors retained the same 
degree of functionality as compared with non-
fused receptors (Figure 1D). Biotinylation 
experiments using a non-membrane permeable 
biotin were performed to provide a more 
accurate determination of receptor expression at 
the plasma membrane. HEK-293T cells were co-
transfected with GHS-R1a-YFP cDNA (1 µg) 
and increasing amounts of GHS-R1b-Rluc 
cDNA (0, 0.1, 0.2, 0.3 or 0.6 µg) or only with 
GHS-R1b-Rluc cDNA (0.3 µg). Total expression 
of GHS-R1a-YFP (YFP fluorescence: 20,000 ± 
2000 units) did not significantly change by 
increasing the expression of GHS-R1b-Rluc 
(Rluc luminescence: 10,000 to 300,000 units). 
To determine the relative expression of GHS-
R1b respect to GHS-R1a (GHS-R1b/GHS-R1a) 
in transfected cells, we performed parallel 
experiments in which HEK-293T cells were 
transfected with increasing amounts of GHS-
R1a-YFP cDNA (up to 1.5 µg) or GHS-R1b-
YFP cDNA (up to 0.6 µg) and the relative total 
expression of receptors was calculated by 
Western blot using an anti-YFP antibody. 
Linearity of transfected cDNA versus Western 
blot signal or versus fluorescence was obtained 
in both cases (transfected cDNA, in µg, versus 
fluorescence values, in arbitrary units gave 
linear plots with slopes of 0.885 and 0.099 
respectively), which allowed the accurate 
determination of the relative GHS-R1b/GHS-
R1a expression ratio. Co-transfection with 1 µg 
of GHS-R1a-YFP and with 0, 0.1, 0.2, 0.3 or 0.6 
µg of GHS-R1b-YFP gave GHS-R1b/GHS-R1a 
ratios of 0, 0.25, 0.5, 1.4 and 5, respectively.  
Biotinylation experiments demonstrated that 
transfected GHS-R1a was always present in the 
plasma membrane, with or without co-
transfection with GHS-R1b, and that co-
transfection with GHS-R1b resulting in GHS-
R1b/GHS-R1a ratios from 0.25 to 5 led to an 
inverted U-shape in the relative expression of 
GHS-R1a in the plasma membrane (Fig. 1E). As 
a negative control, no changes in GHS-R1a 
expression at the plasma membrane were 
detected upon co-transfection with increasing 
amounts of cannabinoid CB1R-Rluc cDNA (Fig. 
1F, CB1R/GHS-R1a expression ratio was 
calculated as above using the slope value of 
0.139 corresponding to linear plots of 
transfected CB1R-YFP cDNA, in µg, versus 
fluorescence values, in arbitrary units). 
Furthermore, biotinylation also demonstrated a 
linear increase in the plasma membrane 
expression of GHS-R1b upon increasing 
transfected amounts of GHS-R1b-YFP cDNA 
(Fig. 1G). These data indicate that GHS-R1b 
differentially modulates GHS-R1a expression at 
the plasma membrane level as a function of 
GHS-R1b/GHS-R1a expression ratio.  
GHS-R1b-mediated modulation of GHS-
R1a signaling in transfected HEK-293T cells- 
The role of GHS-R1b on GHS-R1a signaling 
was evaluated in HEK-293T cells expressing the 
same amount of GHS-R1a-YFP (fluorescence: 
20000 ± 2000) and increasing amounts of GHS-
R1b-Rluc (0 to 5 GHS-R1b/GHS-R1a ratio). 
First, the effect of GHS-R1b on GHS-R1a 
signaling was determined with a dynamic mass 
redistribution (DMR) label-free assay (see 
Materials and Methods), which can detect 
ligand-induced changes in light diffraction in the 
bottom 150 nm of a cell monolayer mostly 
dependent on G-protein-dependent signaling 
(12). Ghrelin (10, 30 and 100 nM) induced a 
dose- and time-dependent signaling in cells only 
transfected with GHS-R1a-YFP, which was 
inhibited by the GHS-R1a antagonist YIL781 
(Fig. 2A). Ghrelin-induced DMR was 
completely blocked by pertussis toxin (PTX), 
but not by cholera toxin (CTX) or the Gq 
inhibitor YM254890 (Fig. 2B), indicating a 
predominant ghrelin-mediated Gi/o protein 
coupling to GHS-R1a in HEK-293T cells. As 
expected, ghrelin did not produce any significant 
effect in cells only expressing GHS-R1b-Rluc 
(Fig. 3A). Ghrelin-mediated DMR signal was 
then analyzed upon three different GHS-
R1b/GHS-R1a expression ratios: 0.5, 1.4, and 5. 
At a GHS-R1b/GHS-R1a expression ratio of 0.5, 
ghrelin was significantly more efficient than 
when the cells were only transfected with GHS-
R1a (Fig. 2C, D). Taking also into account the 
results of biotinylation experiments, these results 
suggest that low relative GHS-R1b expression 
potentiates ghrelin-induced Gi/o protein-
mediated signaling by facilitating GHS-R1a 
trafficking to the plasma membrane. However, 
progressively increasing the relative expression 
of GHS-R1b led to a progressive decrease in 
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signaling, which went down to an almost 
complete lack of effect of ghrelin with a GHS-
R1b/GHS-R1a expression ratio of 5 (Fig. 2C, 
D). This switch from facilitation to inhibition of 
ghrelin-induced Gi/o protein-mediated signaling 
cannot be explained by a GHS-R1b-mediated 
modulation of GHS-R1a trafficking, since 
plasma membrane expression of GHS-R1a was 
the same at the highest GHS-R1b/GHS-R1a 
expression ratio than in cells not co-transfected 
with GHS-R1b (see Fig 1E). According to the 
predominant coupling to Gi/o protein, ghrelin 
dose-dependently decreased forskolin-induced 
cAMP accumulation in cells only expressing 
GHS-R1a (Fig. 4A). Again this effect was not 
observed in cells only transfected with GHS-R1b 
(Fig. 3B), was inhibited by YIL781 (Fig. 4A) 
and was dependent on the GHS-R1b/GHS-R1a 
expression ratio, with ghrelin being more 
efficient, similarly efficient and inefficient at 
expression ratios of 0.5, 1.4 and 5, respectively, 
when compared with cells only transfected with 
GHS-R1a (Fig. 4B). 
Ghrelin also induced a dose-dependent 
increase in cytosolic Ca2+ (Figs. 5A, B), β 
arrestin-2 recruitment (Fig. 5C) and ERK1/2 
phosphorylation (Fig. 5D) in HEK-293T cells 
only transfected with GHS-R1a. All measured 
ghrelin-activated signaling pathways were also 
inhibited by YIL781 (Fig. 5) and they were not 
observed in cells only transfected with GHS-R1b 
(Fig. 3C-E). Importantly, these three signaling 
mechanisms were dependent on the GHS-
R1b/GHS-R1a expression ratio (Fig. 5). As 
observed with DMR and cAMP accumulation 
experiments, at GHS-R1b/GHS-R1a expression 
ratios of 0.5, 1.4 and 5, ghrelin was more 
efficient, similarly efficient and significantly less 
efficient or inefficient, respectively, when 
compared with cells only transfected with GHS-
R1a (Fig. 5).  
Homodimers and heterotetramers of 
GHS-R1a and GHS-R1b in HEK-293T 
transfected cells- Biotinylation and signaling 
experiments therefore did not support a 
preferential intracellular localization of GHS-
R1b and GHS-R1a retention upon intracellular 
heteromerization with GHS-R1b as the basis for 
a dominant negative effect of GHS-R1b on 
GHS-R1a function (6,7). Our results instead fit 
with a negative effect of GHS-R1b on GHS-R1a 
signaling upon heteromerization in the plasma 
membrane (5). Since GPCR homodimers seem 
to be a predominant species and oligomeric 
entities are viewed as multiples of dimers (13), 
we also investigated the possibility of 
homodimerization of GHS-1b and 
heteromerization of GHS-R1a and GHS-R1b 
homodimers. Saturable BRET curves were 
obtained in HEK-293T cells expressing a 
constant amount of GHS-R1a-Rluc and 
increasing amounts of GHS-R1a-GFP2 (Fig. 6A, 
BRETmax of 82 ± 6 mBU and BRET50 of 55 ± 
13) or a constant amount of GHS-R1b-Rluc and 
increasing amounts of GHS-R1b-YFP (Fig. 6B, 
BRETmax of 124 ± 12 mBU and BRET50 of 52 ± 
16), strongly suggestive of homodimerization. 
As negative controls, linear plots with low 
BRET values were obtained using either CB1R-
Rluc (Fig. 6A) or corticotropin-releasing factor 
receptor CRF1-Rluc (Fig. 6B). The sequential 
Resonance Energy Transfer (SRET; 14) assay 
was then used to evaluate the possibility of 
direct interactions between three receptor 
molecules, either two GHS-R1a and one GHS-
R1b or two GHS-R1b and one GHS-R1a, as 
depicted in Figs. 6C and 6D. In this assay, Rluc 
was fused to one of the receptor units to act as a 
BRET donor, GFP2 was fused to a second 
receptor unit to act as a BRET acceptor and as a 
FRET donor and YFP was fused to the third 
receptor unit to act as a FRET acceptor. The 
cDNA constructs were transfected in HEK-293T 
cells and YFP emission was determined after 
adding DeepBlueC as luciferase substrate. 
Positive SRET saturation curves were obtained 
with transfection of a constant amount of GHS-
R1b-Rluc and GHS-R1a-GFP2 and increasing 
amounts of GHS-R1a-YFP (Fig. 6C) or 
increasing amounts of GHS-R1b-YFP  (Fig. 
6D), with SRETmax values of 222 ± 18 mSU and 
40 ± 5 mSU and SRET50 values of 48 ± 14 and 
72 ± 20, respectively. As negative controls, 
linear plots with low SRET values were obtained 
when CB1R-Rluc was transfected as BRET 
donor of GHS-R1a or GHS-R1b FRET pairs 
(Figs. 6C, D). These results show the ability of 
GHS-R1a and GHS-R1b to assemble as 
heterotrimers and possibly heterotetramers. 
Support for heterotetramer formation was 
obtained by using BRET with double 
bimolecular luminescence and fluorescence 
complementation assays (15,16). In this assay, 
the two BRET sensors, the donor Rluc8 (a more 
efficient variant of Rluc) and the acceptor YFP 
Venus (a more efficient variant of YFP) are split 
in two hemiproteins with each split sensor being 
fused to one of the four putative interacting 
receptors. BRET indicates reconstitution of both 
sensors and close proximity of the four 
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receptors. A saturable BRET curve (BRETmax of 
111 ± 10 mBU and BRET50 of 7 ± 2) was 
detected in HEK-293T cells co-transfected with 
equal amounts of GHS-R1a-cRluc and GHS-
R1b-nRluc cDNAs and increasing amounts of 
GHS-R1a-cYFP and GHS-R1b-nYFP cDNAs 
(Fig. 6E). Negative controls were cells 
transfected with adenosine A1R-cRluc cDNA 
instead of GHS-R1a-cRluc cDNA (Fig. 6E). 
Collectively, these results indicate that GHS-R1a 
and GHS-R1b receptors can form oligomeric 
complexes that include heteromers of 
homodimers. 
Differential GHS-R1b-mediated 
modulation of GHS-R1a signaling in rat striatal 
and hippocampal neurons- The significance of 
GHS-R1a-mediated signaling and its modulation 
by heteromerization with GHS-R1b was then 
addressed in primary neuronal cultures from 
striatum and hippocampus, brain areas that 
express functional GHS-R1a receptors (3,4). The 
relative expression of both GHS-R1a and GHS-
R1b, determined by RT-PCR, was higher in 
striatal compared to hippocampal primary 
cultures (Figs. 7A). DMR was first analyzed to 
evaluate ghrelin-mediated signaling and a dose-
dependent response was obtained in both 
primary cultures (Fig. 7B-D). Ghrelin was more 
potent and efficient in striatal than hippocampal 
neurons and its effects were counteracted by 
YIL781 in both preparations (Fig. 7B-D). As 
shown in Fig. 7A, the relative expression of 
GHS-R1b was higher than GHS-R1a in striatal 
neurons, while the opposite, a higher relative 
expression of GHS-R1a than GHS-R1b, was 
observed in hippocampal neurons. Therefore, 
from the results obtained in HEK-293T cells we 
anticipated that an increase in GHS-R1b 
expression could lead to opposite effects in 
hippocampal and striatal neurons. Indeed, in 
hippocampal primary cultures, transfection with 
increasing amounts of GHS-R1b cDNA (0.1 µg 
and 0.5 µg) led to a progressive significant 
increase in the efficacy of ghrelin-induced DMR 
(Fig. 8A, C), while in striatal primary cultures 
GHS-R1b transfection led to the opposite effect 
(Fig. 8B, C). By analyzing another signaling 
readout, cAMP accumulation, unexpected results 
were obtained as compared to HEK-293T cells 
in both hippocampal and striatal primary 
cultures. Ghrelin produced an increase in cAMP 
production with an inverted U-shaped dose-
response (maximal effect at about 100 nM), 
indicating an agonist-induced desensitization 
effect (Figs. 8D, E). This effect was blocked by 
YIL781 in both preparations (Figs. 8D, E, black 
bars). The same as for DMR, in hippocampal 
and striatal primary cultures, transfection with 
increasing amounts of GHS-R1b cDNA (0.1 µg 
and 0.5 µg) led to a progressive significant 
increase and decrease, respectively, in the effect 
of ghrelin-induced cAMP accumulation (Figs. 
8D, E). The results showed that also in neurons 
GHS-R1b can positively or negatively modulate 
GHS-R1a function depending on the 
endogenous relative GHS-R1b/GHS-R1a 
expression ratio. 
Dopamine D1R interacts with GHS-R1a-
GHS-R1b heteromers promoting coupling to 
Gs/olf protein- Previous studies have suggested 
that GHS-R1a-mediated signaling depends 
mostly on Gq coupling, although in HEX 293T 
cells in this study, evidence for Gi/o coupling 
has also been obtained (see Discussion). 
Similarly, ghrelin-induced cAMP-PKA signaling 
has also been reported, but suggested to be 
independent of Gs/olf proteins (see Discussion). 
The G protein subtype involved in ghrelin-
induced cAMP accumulation in striatal and 
hippocampal neurons in culture was first 
investigated by using Gs/olf toxin CTX, Gi/o 
toxin PTX and the Gq protein inhibitor 
YM254890. CTX, but not PTX or YM254890 
prevented ghrelin-induced cAMP in both 
preparations (Fig. 9A, B), identifying Gs/olf as 
predominant G proteins coupled to GHS-R1a in 
neurons. Although CTX increased basal levels 
of cAMP by about two to three fold, this cannot 
explain an apparent inhibition of the effect of 
ghrelin due to saturation on the activation of 
adenylyl cyclase, since under the same 
experimental conditions forskolin increased 
cAMP levels by ten fold (data not shown). A 
possible explanation for the unexpected 
preferential coupling of GHS-R1a to Gs/olf in 
neurons versus Gi/o in HEK-293T cells could be 
the presence in neuronal primary cultures of 
additional receptors that could interact with 
GHS-R1a or GHS-R1b. Indeed, dopamine D1R 
is a canonical mediator of adenylyl cyclase 
activation that has been reported to heteromerize 
with GHS-R1a (17,18). We then investigated its 
possible involvement in ghrelin-mediated cAMP 
accumulation in neurons in culture. In fact, the 
D1R antagonist SCH 23390 (1 µM), but not the 
dopamine D2R antagonist raclopride (1 µM), 
blocked ghrelin-induced cAMP accumulation in 
striatal, but not hippocampal, neurons in culture 
(Fig. 9C, D). That D1R co-expression can 
promote a switch in G protein coupling of GHS-
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R1a, from Gi/o to Gs/olf, was then demonstrated 
in HEK-293T cells transfected with GHS-R1b-
Rluc cDNA (0.2 µg), GHS-R1a-YFP cDNA (1 
µg; GHS-R1b/GHS-R1a ratio of 1.4) and D1R 
cDNA (0.4 µg; Fig. 10A) or D2R cDNA (0.4 µg; 
Fig. 10B). In the presence of D1R, both ghrelin 
(100 nM) and the D1R agonist SKF81297 (100 
nM) increased cAMP production, an effect that 
was blocked by CTX but not by PTX or the Gq 
inhibitor YM254890 (Fig. 10A). In the presence 
of D2R, both ghrelin (100 nM) and the D2R 
agonist quinpirole (1 µM) decreased cAMP 
production, an effect that was blocked by PTX 
but not by CTX or the Gq inhibitor YM254890 
(Fig. 10B). Fig. 10C demonstrates agonist 
selectivity at the concentrations used in cAMP 
experiments using cells only transfected with 
single receptors. In cells transfected with GHS-
R1a, GHS-R1b and D1R, co-activation of GHS-
R1a and the D1R with ghrelin (100 nM) and 
SKF81297 (100 nM) did not produce an additive 
or synergistic effect (Fig. 10D), but blockade of 
either receptor with D1R antagonist SCH23390 
(1 µM) or the GHS-R1a antagonist YIL781 (1 
µM) completely counteracted cAMP 
accumulation induced by both ghrelin and 
SKF81297 (Fig. 10D). Since the interactions 
between GHS-R1a and D1R ligands, particularly 
the cross-antagonism (see Discussion) strongly 
suggested oligomerization, we investigated this 
possibility with BRET experiments. In HEK-
293T cells transfected with a constant amount of 
D1R-Rluc cDNA (0.4 µg) and increasing 
amounts of GHS-R1a-YFP cDNA (0.2 to 1.5 µg) 
(Fig. 11A) or GHS-R1b-YFP cDNA (0.1 to 0.6 
µg) (Fig. 11B) low and linear plots were 
observed, consistent with non-specific 
interactions. Similarly, low BRET values were 
obtained (at a YFP/Rluc ratio of 100) when cells 
where exposed to ghrelin, the D1R agonist 
SKF81297, or both (100 nM in all cases; Figs. 
11C, D). Nevertheless, a saturable BRET curve 
was obtained when cells were transfected with 
D1R-Rluc cDNA (0.4 µg), increasing amounts of 
GHS-R1b-YFP cDNA (0.1 to 0.6 µg) and GHS-
R1a cDNA (0.8 µg), with BRETmax and BRET50 
values of 36 ± 6 mBU and 93 ± 10, respectively 
(Fig. 11E, black line), indicating that D1R 
specifically interacts with GHS-R1a-GHS-R1b 
heteromers. In agreement, significant BRET 
values could only be obtained in cells 
transfected with D1R-Rluc cDNA (0.4 µg) and 
GHS-R1a-GFP2 (1.0 µg) when co-transfected 
with increasing amounts of GHS-R1b cDNA 
(0.05 to 0.3 µg) (Fig. 11F). BRET saturation 
curves were also obtained in cells transfected 
with D1R-Rluc cDNA (0.4 µg), increasing 
amounts of GHS-R1b-YFP cDNA (0.1 to 0.6 
µg) and GHS-R1a cDNA (0.8 µg) and treated 
with 100 nM SKF81297 (Fig. 11E, red line; 
BRETmax and BRET50 values of 34 ± 3 mBU and 
25 ± 11, respectively), 100 nM ghrelin (Fig. 
11E, green line; BRETmax and BRET50 values of 
of 46 ± 3 mBU and 99 ± 12, respectively) or 
both (Fig. 11E, blue line; BRETmax and BRET50 
values of of 52 ± 3 mBU and 39 ± 9, 
respectively). The significant increase in 
BRETmax upon treatment with ghrelin indicates a 
facilitation of energy transfer or an increase in 
heteromer formation, while the significant 
decrease in BRET50 upon treatment with 
SKF81297 suggests an increase in the affinity of 
the interaction between receptors. Both effects, a 
significant increase in BRETmax and a significant 
decrease in BRET50, were observed upon co-
treatment with ghrelin and SKF81297 
(significant statistical differences in BRETmax 
and BRET50 as compared to control non-treated 
cells were determined by ANOVA followed by 
Bonferroni’s corrections: *p<0.05 in all cases). 
If D1R can only interact with GHS-R1a in the 
presence of GHS-R1b, the absence of GHS-R1b 
should disclose the properties that are dependent 
on GHS-R1a-GHR1b-D1R heteromerization. In 
fact, in cells transfected with D1R but only co-
transfected with GHS-R1a, ghrelin (100 nM) did 
not produce cAMP accumulation and YIL781 (1 
µM) did not counteract cAMP accumulation 
induced by SKF81297 (100 nM) (Fig. 12). 
Altogether, the results from transfected HEK-
293T cells provide a very plausible mechanism 
for the results obtained in striatal cells in culture, 
demonstrating that GHS-R1b determines the 
ability of GHS-R1a to form oligomeric 
complexes with D1R, which allows ghrelin to 
activate Gs/olf protein-mediated signaling.   
 
DISCUSSION 
Previous studies about the role of the 
truncated ghrelin receptor GHS-R1b only 
indicated a possible dominant negative effect, 
which could depend on its ability to retain the 
full and functional ghrelin receptor GHS-R1a in 
intracellular compartments (6,7) or to stabilize 
GHS-R1a in a non-signaling conformation (5). 
The present study does not support the 
intracellular mechanism as a main regulatory 
mechanism. Instead, it reveals a novel and 
complex modulatory role of GHS-R1b in the 
trafficking and signaling of GHS-R1a. First, 
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GHS-R1b facilitates GHS-R1a trafficking to the 
plasma membrane with an efficiency that 
depends on a specific relative GHS-R1b/GHS-
R1a expression ratio. With further increases in 
the GHS-R1b/GHS-R1a expression ratio this 
facilitation declines and disappears. Thus, higher 
and probably non-physiological amounts of 
GHS-R1b seem to be necessary to promote 
intracellular retention of GHS-R1a (6,7). 
Second, GHS-R1b impairs GHS-R1a signaling 
upon oligomerization at the plasma membrane. 
The correlation between the results obtained 
with biotinylation and signaling experiments in 
HEK-293T cells demonstrates that the main 
factor determining the potency of ghrelin-
induced signaling is the stoichiometric 
relationship of both proteins in the plasma 
membrane. Therefore, GHS-R1b can act as a 
dual modulator of GHS-R1a function: low 
relative GHS-R1b expression potentiates and 
high relative GHS-R1b expression inhibits GHS-
R1a function by facilitating GHS-R1a 
trafficking to the plasma membrane and by 
exerting a negative allosteric effect on GHS-R1a 
signaling, respectively. The ability of GHS-R1a 
homodimers to oligomerize with one or several 
(at least two) GHS-R1b protein molecules 
provides a frame for oligomerization to be 
involved in this fine-tuning stoichiometry-
dependent modulation of GHS-R1a function. 
Since GHS-R1a seems to be the minimal 
functional unit (19), one possible scenario is that 
one GHS-R1b molecule per one GHS-R1a 
homodimer facilitates trafficking but not a 
negative allosteric modulation of ghrelin, while 
two (or more) GHS-R1b molecules would not 
facilitate trafficking, but would allosterically 
decrease ghrelin-mediated signaling.  
To our knowledge, this is the first study 
that addresses the modulatory role of GHS-R1b 
on GHS-R1a signaling in primary neurons in 
culture, which offers a more physiological 
model than previously used mammalian 
transfected cell lines. The results first indicate 
that endogenous relative expression of GHS-R1a 
and GHS-R1b are in the same range in primary 
neuronal cultures that in our experiments in 
HEK-293T transfected cells. Significantly, from 
the experiments in HEK-293T cells, predictable 
changes in ghrelin-induced signaling were 
demonstrated in striatal and hippocampal 
neurons in culture upon varying the relative 
levels of expression of GHS-R1b. Progressively 
increasing the expression of GHS-R1b in 
hippocampal and striatal cell cultures led to an 
increase and decrease in ghrelin-induced 
signaling, respectively, which depended on a 
respective initially low and high relative GHS-
R1a/GHS-R1b expression ratio.  
In isolation, the GHS-R1a receptor has 
been shown to couple to Gq proteins, resulting 
in activation of phospholipase C (PLC), inositol 
triphosphate (IP3) and Ca2+ mobilization 
(5,19,20), but it has also been reported to 
produce signaling dependent on pertussis toxin-
sensitive Gi/o proteins (21,22). Thus, ghrelin 
seems to be able to activate different signaling 
pathways in a tissue-specific manner. In 
pituitary GH cells, GHS-R1a seems to couple 
preferentially to Gq, leading to stimulation of 
GH release, while in islet pancreatic β-cells it 
couples to Gi/o proteins and its activation leads 
to inhibition of insulin release (23). It has also 
been reported that ghrelin can produce cAMP-
PKA signaling, although generally not attributed 
to its canonically dependent stimulatory Gs 
protein (24-26). The use of selective G protein 
toxins and inhibitors demonstrated a preferential 
Gi/o-coupling of the GHS-R1a-GHS-R1b 
complex in HEK-293T cells and, unexpectedly, 
a preferential Gs/olf coupling in both striatal and 
hippocampal neurons in culture. In HEK-293T 
cells the same modulation by GHS-R1b was 
observed for GHS-R1a-mediated inhibition of 
adenylyl cyclase, β arrestin-2 recruitment, 
ERK1/2 phosphorylation and cytosolic Ca2+ 
increase. Although a canonical Gq-coupled 
signaling, cytosolic Ca2+ increase can also be 
induced by Gi-associated βγ-dependent 
mechanisms, as demonstrated in several 
mammalian cell lines, including HEK-293 cells 
(27,28). ERK1/2 phosphorylation could then 
depend on a downstream effect of cytosolic Ca2+ 
increase or β arrestin-2 recruitment (28,29).  
The present study demonstrates that 
oligomerization with GHS-R1b, confers the 
GHSR1a-GHSR1b complex the ability to 
heteromerize with D1R, allowing ghrelin to 
signal through Gs/olf. Thus, in HEK-293T cells 
transfected with GHS-R1a and GHS-R1b, co-
transfection of D1R promoted a switch of 
ghrelin-mediated signaling from Gi/o to Gs/olf 
signaling. A previous study on transfected HEK-
293 cells suggested that GHS-R1a can 
heteromerize and functionally interact with D1R, 
but apparently without concomitant interaction 
with GHS-R1b. The same study also suggested 
that within the GHS-R1a-D1R heteromer ghrelin 
amplifies D1R signaling (17). A more recent 
study by the same research group also suggests 
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that GHS-R1a-D1R heteromerization allows 
D1R to couple and signal through Gq proteins, 
again without the involvement of GHS-R1b 
(18). However, our BRET experiments show 
that GHS-R1a-D1R heteromerization depends 
on the presence of GHS-R1b in the complex. In 
cells co-transfected with D1R, GHS-R1a and 
GHS-R1b, ghrelin (maximal effective 
concentration) does not potentiate and, if 
anything, decreases cAMP accumulation 
induced by SKF81297. Furthermore, a 
significant cross-antagonism, a common 
biochemical property of receptor heteromers was 
also observed. This is the ability of an antagonist 
of one of the protomers to counteract the 
signaling induced by an agonist of the other 
protomer in a receptor heteromer (13). In cells 
transfected with GHS-R1a, GHS-R1b and D1R, 
both the D1R antagonist SCH23390 and the 
GHS-R1a antagonist YIL781 were able to block 
both SKF81297- and ghrelin-induced cAMP 
increases. The cross-antagonism of SCH23390 
on ghrelin-induced cAMP accumulation was 
also observed in striatal, but not in hippocampal 
cells in culture. Furthermore, ghrelin-induced 
cAMP accumulation in striatal cells was 
dependent on the relative expression of GHS-
R1b. The total correlation among the results 
obtained in HEK-293T and striatal cells 
indicates the presence of the same D1R-GHS-
R1a-GHS-R1b complexes in striatal cells. In 
hippocampus, although evidence for molecular 
and functional interactions between hippocampal 
GHS-R1a and D1R have been recently reported 
(18), receptors other than D1R might be 
responsible for coupling GHS-R1a-GHS-R1b 
heteromers to Gs-olf protein, suggesting that 
different complexes containing GHS-R1a-GHS-
R1b heteromers can be differentially expressed 
in the brain.  
In summary, GHS-R1b plays a much 
more active and complex role in ghrelin-induced 
signaling than previously assumed. The present 
study indicates that the relative expression of 
GHS-R1b not only determines the efficacy of 
ghrelin-induced GHS-R1a-mediated signaling, 
but also determines the ability of GHS-R1a to 
form oligomeric complexes with other receptors 
promoting profound qualitative changes in 
ghrelin-induced signaling. 
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FIGURE LEGENDS 
 
FIGURE 1. GHS-R1b modulates plasma membrane expression of GHS-R1a in HEK-293T cells. 
In A, B and C, confocal microscopy images of HEK-293T cells transfected with GHS-R1a-YFP 
cDNA (1.5 µg), GHS-R1b-Rluc (0.5 µg) or both are shown. GHS-R1a-YFP was identified by its own 
fluorescence (green) and GHS-R1b-Rluc by a monoclonal anti-Rluc primary antibody and a cyanine-
3-conjugated secondary antibody (red); in C, colocalization of both receptors is shown in yellow. Cell 
nuclei were stained with Hoesch (blue) and scale bars = 10 µm. In D, cAMP was determined in HEK-
293T cells transfected with cDNA (1.5 µg) from the indicated receptors or fusion proteins; cells were 
exposed for 15 min to vehicle or ghrelin (100 nM) in the presence of forskolin (0.5 µM); values are 
means ± S.E.M. of 3-4 experiments and expressed as decreases (%) versus forskolin alone (100%; 
dotted line); no statistical differences between differently transfected cells were found by ANOVA 
followed by Bonferroni’s corrections (p>0.05). In E-G, biotinilation experiments were performed in 
HEK-293T cells co-transfected with GHS-R1a-YFP cDNA (1 µg) and increasing amounts of GHS-
R1b-Rluc cDNA (0 to 0.6 µg) or GHS-R1b-Rluc cDNA alone (0.5 µg) (E), GHS-R1a-YFP cDNA (1 
µg) and increasing amounts of CB1R-Rluc cDNA (0 to 1 µg) (F), or increasing amounts of GHS-R1b-
Rluc cDNA (0.05 to 0.6 µg) (G). In E-G, quantification of immunoreactive bands from 4-6 
independent experiments; values represent mean ± S.E.M. of the percentage of GHS-R1a-YFP 
membrane expression versus control cells (cells not expressing GHS-R1b-Rluc or CB1R-Rluc) (E, F) 
or the percentage of GHS-R1b-Rluc membrane expression versus control cells (non-transfected cells) 
(G); statistical differences of differently transfected cells were analyzed by ANOVA followed by 
Bonferroni’s corrections: *p<0.05 and *** p<0.001, as compared to control cells; representative 
Western blots are shown in the bottom. 
 
FIGURE 2. GHS-R1b modulates GHS-R1a signaling detected by DMR in HEK-293T cells. DMR 
was determined in HEK-293T cells transfected with GHS-R1a-YFP cDNA (1 µg) (A, B) or co-
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transfected with GHS-R1a-YFP cDNA (1 µg) and increasing amounts of GHS-R1b-Rluc cDNA (0.05 
to 0.6 µg) to obtain 0.5, 1.4 and 5 GHS-R1b-Rluc/GHS-R1a-YFP ratio (C, D). Cells were pre-treated 
overnight with vehicle (A, C, D) or with pertussis toxin (PTX; 10 ng/ml), cholera toxin (CTX; 100 
ng/ml) or the Gαq inhibitor YM254890 (YM; 1 µM)(B) followed by treatment (15 min) with vehicle 
or the GHS-R1a antagonist YIL781 (2 µM) and activated with increasing concentrations of ghrelin 
(10, 30 and 100 nM, A, C, D) or with 30 nM ghrelin (B). Representative picometer-shifts of reflected 
light wavelength (pm) versus time curves are shown in A and C; each curve represents the mean of an 
optical trace experiment carried out in triplicate. In B, maximum responses at 500 seconds are derived 
from the corresponding picometer shifts of reflected light wavelength versus time curves. In D, 
maximum responses at 500 seconds induced by different ghrelin concentrations (10 to 100 nM) are 
compared for GHS-R1b-Rluc/GHS-R1a-YFP ratios from 0 to 5; values are derived from curves in A 
and C. Statistical differences of the effect of ghrelin between cells treated with PTX as compared to 
vehicle treated cells (B) or in cells transfected with different GHS-R1b/GHS-R1a ratios as compared 
to cells only expressing GHS-R1a (D) were analyzed by ANOVA followed by Bonferroni’s 
corrections: *p<0.05, **p<0.01 and *** p<0.001. 
 
FIGURE 3. Lack of functionality of GHS-R1b when expressed without GHS-R1a. DMR (A), 
cAMP accumulation (B), cytosolic Ca2+ increases (C), β arrestin-2 recruitment (D) and ERK1/2 
phosphorylation (E) were determined in HEK-293T cells transfected with 0.4 µg of GHS-R1b-Rluc 
cDNA; cells were pre-treated (15 min) with vehicle or the GHS-R1a antagonist YIL781 (YIL; 2 µM) 
followed by activation (15 min) with increasing concentrations of ghrelin in the absence (A, C, D, E) 
or in the presence (B) of 0.5 µM forskolin (FK); values are means ± S.E.M. of 4-5 experiments 
 
FIGURE 4. GHS-R1b modulates GHS-R1a-mediated inhibition of adenylyl cyclase in HEK-
293T cells. cAMP accumulation was determined in HEK-293T cells transfected with GHS-R1a-YFP 
cDNA (1 µg) (A) or co-transfected with GHS-R1a-YFP cDNA (1 µg) and increasing amounts of 
GHS-R1b-Rluc cDNA (0.05 to 0.6 µg) to obtain 0.5, 1.4 and 5 GHS-R1b-Rluc/GHS-R1a-YFP ratio 
(B). Cells were incubated overnight with vehicle or pertussis toxin (PTX; 10 ng/ml) or 2 h with 
cholera toxin (CTX; 100 ng/ml) and pre-treated (15 min) with vehicle or the GHS-R1a antagonist 
YIL781 (2 µM) followed by activation (15 min) with ghrelin in the absence or in the presence of 0.5 
µM forskolin (FK). Values are means ± S.E.M. of 5-6 experiments per treatment and expressed as 
decreases of forskolin induced cAMP accumulation (100%; dotted line). Statistical differences of the 
effect of differently treated cells under differently transfected conditions were analyzed by ANOVA 
followed by Bonferroni’s corrections: *p<0.05 and *** p<0.001, as compared to the effect of 
forskolin alone. 
 
FIGURE 5. GHS-R1b modulates GHS-R1a-mediated cytosolic Ca2+ increase, β arrestin-2 
recruitment and ERK1/2 phosphorylation. In A and B, HEK-293T cells were transfected with 
GHS-R1a-YFP cDNA (1 µg) or co-transfected with GHS-R1a-YFP cDNA (1 µg) and increasing 
amounts of GHS-R1b-Rluc cDNA (0.05 to 0.6 µg) to obtain 0.5, 1.4 and 5 GHS-R1b-Rluc/GHS-R1a-
YFP ratio. In A, representative intracellular curves of Ca+2 release over time are shown. In B, values 
of maximal Ca+2 release (means ± S.E.M.; n = 4-6) induced by 30 nM ghrelin were derived from the 
curves obtained at the different GHS-R1b-Rluc/GHS-R1a-YFP ratios. In C, β-arrestin-2 recruitment 
(expressed as mBU; means ± S.E.M; n = 5-7) was measured by BRET experiments in cells 
transfected with 1 µg of β-arrestin-2-Rluc cDNA and 1 µg of GHS-R1a-YFP cDNA in the absence or 
the presence of GHS-R1b cDNA (0.05 to 0.6 µg). In all cases, cells were pre-treated (15 min) with 
vehicle or the GHS-R1a antagonist YIL781 (2 µM) followed by activation with ghrelin 30, 100 or 300 
nM. In D, ERK1/2 phosphorylation from the same transfected cell groups and treatments as in C, 
expressed as a percentage over values found in non-transfected cells (means ± S.E.M; n = 5-7); 
representative Western blots are shown in the bottom. Statistical differences of the effect of different 
GHS-R1b/GHS-R1a ratios in differently treated conditions were analyzed by ANOVA followed by 
Bonferroni’s corrections: *p<0.05, as compared to cells only expressing GHS-R1a. 
 
FIGURE 6. Heterotetramers of GHS-R1a and GHS-R1b homodimers in HEK-293T cells. In A 
and B, GHS-R1a and GHS-R1b homodimers were detected by BRET saturation experiments in HEK-
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293T cells co-transfected with GHS-R1a-Rluc cDNA (1.5 µg) and increasing amounts of GHS-R1a-
GFP2 cDNA (0.5 to 3 µg) (A) or a constant amount of GHS-R1b-Rluc cDNA (0.3 µg) and increasing 
amounts of GHS-R1b-YFP (0.05 to 0.6 µg) (B). As negative controls, linear and low BRET values 
were obtained transfecting the cDNA corresponding to either cannabinoid receptor CB1R-Rluc (0.5 
µg, A) or corticotropin-releasing factor receptor CRFR1-Rluc (0.3 µg, B) as BRET donors. In C and 
D, positive SRET saturation curves were obtained in HEK-293T cells co-transfected with a constant 
amount of GHS-R1b-Rluc cDNA (0.4 µg) and GHS-R1a-GFP2 cDNA (1.5 µg) and increasing 
amounts of GHS-R1b-YFP cDNA (0.5 to 3 µg, C) or GHS-R1a-YFP cDNA (0.05  to 0.5 µg, D). As 
SRET negative controls, linear and low SRET values were obtained when CB1R-Rluc cDNA (0.4 µg) 
was transfected as BRET donor of GHS-R1a or GHS-R1b FRET pairs (C, D). In E, BiLFC saturation 
curve was obtained in HEK-293T cells co-transfected with equal amounts of cDNA corresponding to 
GHS-R1a-cRluc and GHS-R1b-nRluc (1.5 µg) and increasing amounts of GHS-R1a-cYFP and GHS-
R1b-nYFP cDNAs (0.5 to 2.5 µg for each one). As negative control linear and low BiLFC were 
obtained in cells transfected with adenosine A1R-cRluc cDNA (0.2 µg) instead of GHS-R1a-cRluc 
cDNA. The relative amounts of BRET or SRET are given as a function of 100 x the ratio between the 
fluorescence of the acceptor and the luciferase activity of the donor. BRET and SRET are expressed 
as milliBRET units (mBU) or milliSRET units (mSU) and are given as the means ± standard 
deviation (SD) of 4–5 experiments grouped as a function of the amount of BRET or SRET acceptor.  
 
FIGURE 7. Differential expression of GHS-R1a and GHS-R1b in striatal and hippocampal 
neurons in culture. In A, the relative expression of GHS-R1a and GHS-R1b was determined by RT-
PCR using primary cultures of rat hippocampal (white) and striatal (black) neurons. In C-D, DMR 
was determined in striatal (C) or hippocampal (D) neuronal primary cultures pre-treated (30 min) with 
vehicle or the GHS-R1a antagonist YIL781 (2 µM) and followed by activation with ghrelin (30 or 
100 nM); representative picometer-shifts of reflected light wavelength (pm) versus time curves are 
shown; each curve represents the mean of an optical trace experiment carried out in triplicate. In B, 
maximum responses of DMR at 2000 seconds induced by ghrelin (30 or 100 nM) are compared for 
striatal and hippocampal neuronal cultures; values are means ± S.E.M. of 5-7 experiments performed 
with independent primary cultures. Statistical differences of the expression of GHS-R1a and GHS-
R1b and the effect of ghrelin between hippocampal as compared to striatal cell cultures were analyzed 
by ANOVA followed by Bonferroni’s corrections: **p<0.01 and ***p<0.001. 
 
FIGURE 8. GHS-R1b-mediated modulation of GHS-R1a signaling in striatal and hippocampal 
neurons. In A-C, DMR was determined in rat hippocampal (A, C) and striatal (B, C) primary 
cultures not transfected (black) or transfected with 0.1 µg (blue) or 0.5 µg (green) of GHS-R1b cDNA 
and activated with 100 nM ghrelin; representative picometer-shifts of reflected light wavelength (pm) 
versus time curves are shown in A and B; each curve represents the mean of an optical trace 
experiment carried out in triplicate. In C, ghrelin-induced maximum responses at 2000 seconds are 
compared for striatal and hippocampal neuronal cultures not transfected or transfected with 0.1 µg or 
0.5 µg GHS-R1b cDNA; statistical differences between differently transfected cells for each type of 
culture were analyzed by ANOVA followed by Bonferroni’s corrections: *p<0.05 and *** p<0.001, 
as compared to non-transfected cells. In D and E, cAMP accumulation was determined in rat 
hippocampal (D) and striatal (E) primary cultures not transfected (black) or transfected with 0.1 µg 
(blue) or 0.5 µg (green) GHS-R1b cDNA; cells were pre-treated (15 min) with vehicle or the GHS-
R1a antagonist YIL781 (2 µM) followed by activation (15 min) with increasing ghrelin 
concentrations; values are means ± S.E.M. of 4-6 experiments and expressed as percentage of values 
from non-stimulated cells (100%; dotted line); statistical differences between differently transfected 
cells were analyzed by ANOVA followed by Bonferroni’s corrections: *p<0.05 and *** p<0.001, as 
compared to non-transfected cells. 
 
FIGURE 9. Gs/olf-copling of ghrelin receptors in striatal and hippocampal neurons. In A and B, 
cAMP accumulation was determined in rat striatal (A) and hippocampal (B) primary cultures 
incubated overnight with vehicle, pertussis toxin (PTX; 10 ng/ml) or the Gαq inhibitor YM254890 
(YM; 1µM) or 2 h with cholera toxin (CTX; 100 ng/ml); cells were then treated with vehicle or 
ghrelin (100 nM); values are means ± S.E.M. of 3-4 experiments and are expressed as percentage of 
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the values of vehicle treated cells (100%; dotted line). In C and D, cAMP accumulation was 
determined in rat striatal (A) and hippocampal (B) primary cultures pre-treated (15 min) with vehicle, 
D1R antagonist SCH23390 (SCH; 1 µM) or D2R antagonist raclopride (1 µM) followed by treatment 
(15 min) with vehicle or ghrelin (100 nM); values are means ± S.E.M. of 5-6 experiments and are 
expressed as percentage of the values of vehicle treated cells (100%; dotted line). Statistical 
differences between differently treated cells were analyzed by ANOVA followed by Bonferroni’s 
corrections: *p<0.05, **p<0.01 and *** p<0.001, as compared to vehicle-treated cells; &&p<0.01, as 
compared to ghrelin treated cells. 
 
FIGURE 10. D1R promotes GHS-R1a-GHS-R1b heteromers coupling to Gs/olf protein. cAMP 
accumulation was determined in HEK-293T cells transfected with GHS-R1b-Rluc cDNA (0.2 µg), 
GHS-R1a-YFP cDNA (1 µg) and D1R cDNA (0.4 µg; A, D) or D2R cDNA (0.4 µg; B) or single 
transfected with the same amount of the indicated receptors (C); cells were incubated overnight with 
vehicle, pertussis toxin (PTX; 10 ng/ml) or the Gαq inhibitor YM254890 (YM; 1µM) or 2 h with 
cholera toxin (CTX; 100 ng/ml), pre-treated (15 min) with vehicle, the GHS-R1a antagonist YIL781 
(YIL; 2 µM) or the D1R antagonist SCH23390 (SCH; 1 µM), followed by activation (15 min) with 
ghrelin (100 nM), the D1R agonist SKF81297 (SKF; 100 nM) or the D2R agonist quinpirole (Quin; 1 
µM), alone or in combination in the absence (A, D) or the presence (B, C) of forskolin (FK; 0.5 µM); 
values are means ± S.E.M. of 6-8 experiments and expressed as percentage of values of cells non-
treated with ghrelin (100%; dotted line); statistical differences between differently treated cells were 
analyzed by ANOVA followed by Bonferroni’s corrections: *p<0.05 and **p<0.01, as compared to 
vehicle-treated cells.  
 
FIGURE 11. Selective heteromerization of D1R with GHS-R1a-GH-R1b complexes. BRET 
experiments in HEK-293T cells transfected with a constant amount of D1R-Rluc cDNA (0.4 µg) and 
increasing amounts of GHS-R1a-YFP cDNA (0.2 to 1.5 µg, A) or GHS-R1b-YFP cDNA (0.1 to 0.6 
µg, B). BRET at a YFP/Rluc ratio of 100 was also determined in cells not activated or activated with 
ghrelin (100 nM), the D1R agonist SKF81297 (SKF; 100 nM) or both (C, D). In E, BRET 
experiments were performed in HEK-293T cells transfected with D1R-Rluc cDNA (0.4 µg), GHS-R1a 
cDNA (0.8 µg) and increasing amounts of GHS-R1b-YFP cDNA (0.1 to 0.6 µg), not stimulated 
(black curve) or stimulated with SKF81297 (SKF; 100 nM; red curve), ghrelin (100 nM; green curve) 
or both (blue curve). In F, BRET experiments were performed in HEK-293T cells transfected with 
with D1R-Rluc cDNA (0.4 µg), GHS-R1a-GFP2 cDNA (1.0 µg) and increasing amounts of GHS-R1b 
cDNA (0.05 to 0.3 µg). BRET values are given as a function of 100 x the ratio between the 
fluorescence of the acceptor and the luciferase activity of the donor. BRET is expressed as milliBRET 
units (mBU) and are given as the means ± standard deviation (SD) of 4-6 experiments grouped as a 
function of the amount of BRET acceptor. Statistical differences between differently transfected cells 
were analyzed by ANOVA followed by Bonferroni’s corrections: *p<0.05 and **p< 0.01, as 
compared to cells not transfected with GHS-R1b. 
 
FIGURE 12. Dependence on GHS-R1b for D1R-mediated modulation of GHS-R1a signaling. 
cAMP accumulation was determined in cells transfected with GHS-R1a-YFP cDNA (1.5 µg) and D1R 
cDNA (0.5 µg); cells were treated with vehicle, ghrelin (100 nM) or SKF 81297 (SKF; 100 nM) with 
and without YIL781 (2 µM) or  SCH23390 (SCH; 1 µM) ; values are means ± S.E.M. of 4-6 
experiments and are expressed as percentage values from cells only treated with vehicle (100%; 
dotted line).  Statistical differences between differently treated cells were analyzed by ANOVA 
followed by Bonferroni’s corrections: **p<0.01 and ***p< 0.001, as compared to cells treated only 
with vehicle. 
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